Kliniczne zastosowanie technologii ultradźwiękowej wspomaganej sztuczną inteligencją w przedoperacyjnej ocenie raka tarczycy
Przegląd badań
Status
Status
Warunki
Warunki
Interwencja / Leczenie
Interwencja / Leczenie
Szczegółowy opis
Typ studiów
Typ studiów
Zapisy (Rzeczywisty)
Zapisy
Faza
Faza
- Nie dotyczy
Kontakty i lokalizacje
Kontakt w sprawie studiów
Kontakt w sprawie studiów
- Nazwa: Bo Wang Professor
- Numer telefonu: 13959123550
- E-mail: wangbo@fjmu.edu.cn
Lokalizacje studiów
-
-
Fujian
-
Fuzhou, Fujian, Chiny, 350001
- Fujian Medical University Union Hospital
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Kryteria kwalifikacji
Wiek uprawniający do nauki
- Dziecko
- Dorosły
- Starszy dorosły
Akceptuje zdrowych ochotników
Opis
Kryteria przyjęcia:
- Pacjenci z przedoperacyjnym patologicznym potwierdzeniem nowotworu złośliwego tarczycy poddawani leczeniu chirurgicznemu.
- Pacjenci z łagodnymi nowotworami tarczycy, takimi jak gruczolaki tarczycy powodujące objawy uciskowe, poddawani leczeniu chirurgicznemu.
- Pacjenci z pełnymi i wysokiej jakości tradycyjnymi, dwuwymiarowymi kolorowymi obrazami ultrasonograficznymi.
- Kompletne raporty patologii pooperacyjnej.
- Chęć wzięcia udziału w tym badaniu klinicznym i podpisanie świadomej zgody.
Kryteria wyłączenia:
- Pacjenci po operacji szyi lub radioterapii w wywiadzie.
- Pacjenci, u których w przeszłości występowały nowotwory złośliwe w innych częściach ciała.
- Pacjenci z dysfunkcją tarczycy.
- Niekompletne lub niskiej jakości tradycyjne dwuwymiarowe kolorowe obrazy ultrasonograficzne.
- Niekompletne raporty patologii pooperacyjnej.
- Odmowa udziału w tym badaniu klinicznym.
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Diagnostyczny
- Przydział: Nie dotyczy
- Model interwencyjny: Zadanie dla jednej grupy
- Maskowanie: Brak (otwarta etykieta)
Liczba ramion
Broń i interwencje
Grupa uczestników / ArmGrupa uczestników / Arm |
Interwencja / LeczenieInterwencja / Leczenie |
|---|---|
|
Eksperymentalny: AI-Assisted Preoperative Review
Participants undergo standard preoperative thyroid ultrasonography followed by a standardized AI-assisted repeat examination and surgeon-led review incorporating the locked AI system's thyroid-nodule output.
The AI system does not assess cervical lymph nodes.
All supplementary examinations and final diagnostic and surgical decisions are made by clinicians.
|
After standard preoperative ultrasonography, the same participant underwent a standardized AI-assisted repeat examination.
The locked system identified and classified thyroid nodules and provided malignancy-score information for surgeon-led review.
It did not assess cervical lymph nodes and was not retrained or recalibrated during the study.
Additional fine-needle aspiration, intraoperative pathologic examination, and surgical management were determined by clinicians using the complete clinical assessment.
|
Co mierzy badanie?
Podstawowe miary wyniku
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Proportion of Participants Undergoing Supplementary Cytologic or Pathologic Examination
Ramy czasowe: From completion of the AI-assisted repeat examination through completion of surgery
|
Number and proportion of enrolled participants who underwent at least one additional cytologic or pathologic examination, such as fine-needle aspiration or intraoperative frozen-section examination, after completion of conventional ultrasonography and AI-assisted review and before completion of surgery.
Each participant is counted once regardless of the number of examinations.
The decision remained clinician led; cervical lymph-node examinations were outside the AI system's task.
|
From completion of the AI-assisted repeat examination through completion of surgery
|
|
Proportion of Participants With a Change in Planned Surgical Management
Ramy czasowe: From completion of the AI-assisted review through surgery
|
Number and proportion of enrolled participants with at least one documented change in the surgeon-led planned surgical approach or extent after conventional ultrasonography, AI-assisted review, and any supplementary pathological examination, when performed.
Changes may involve thyroid resection or cervical lymph-node management.
Each participant is counted once regardless of the number of changes.
The AI system provided thyroid-nodule information only and did not assess cervical lymph nodes.
|
From completion of the AI-assisted review through surgery
|
Miary wyników drugorzędnych
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Distribution of C-TIRADS Categories Among Evaluated Thyroid Nodules
Ramy czasowe: During standard preoperative ultrasonography, before the AI-assisted repeat examination
|
Number and percentage of evaluated thyroid nodules in each clinician-assigned C-TIRADS category during conventional ultrasonography.
Nodule size, composition, echogenicity, margins, calcifications, and clinician-assessed cervical lymph-node findings were recorded as descriptive covariates and were not treated as separate outcome measures.
|
During standard preoperative ultrasonography, before the AI-assisted repeat examination
|
|
Proportion of Evaluated Thyroid Nodules Classified as AI-Positive
Ramy czasowe: During the preoperative AI-assisted repeat examination, before surgery
|
Number and percentage of evaluated thyroid nodules with a locked AI malignancy score >0.5.
The AI system evaluated thyroid nodules only and did not assess cervical lymph nodes.
|
During the preoperative AI-assisted repeat examination, before surgery
|
|
Results of Supplementary Cytologic or Pathologic Examinations
Ramy czasowe: From supplementary sampling to availability of the corresponding result, before or during surgery
|
Among participants who underwent at least one additional cytologic or pathologic examination, record the cytologic or histopathologic result for each sampled thyroid nodule or cervical lymph node.
Results are summarized at the examination level as nonmalignant, indeterminate, malignant, or metastatic, as applicable.
|
From supplementary sampling to availability of the corresponding result, before or during surgery
|
|
Final Histopathological Diagnosis of Resected Thyroid Nodules
Ramy czasowe: From surgery until the final postoperative histopathology report became available; assessed through October 15, 2025, over the approximately 14-month study period.
|
For each resected thyroid nodule linked unambiguously to the evaluated lesion, record the final diagnosis as benign, malignant, follicular tumor of uncertain malignant potential (FT-UMP), well-differentiated tumor of uncertain malignant potential (WDT-UMP), non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP), or another borderline diagnosis.
|
From surgery until the final postoperative histopathology report became available; assessed through October 15, 2025, over the approximately 14-month study period.
|
|
Nodule-Level Sensitivity of AI and C-TIRADS
Ramy czasowe: From the preoperative examinations until the final postoperative histopathology report became available; assessed through October 15, 2025, over the approximately 14-month study period.
|
Using definitive postoperative histopathology as the reference standard, sensitivity is TP/(TP + FN), expressed as a percentage, for the locked AI classification (positive if score >0.5) and conventional C-TIRADS (positive if category 4a or higher).
Include only pathology-matched nodules with an unambiguous lesion-level link and a definitive benign or malignant diagnosis.
Exclude FT-UMP, WDT-UMP, NIFTP, other borderline diagnoses, and nodules without unambiguous lesion-level linkage.
These lesion-level exclusions do not alter the 515-participant workflow cohort.
|
From the preoperative examinations until the final postoperative histopathology report became available; assessed through October 15, 2025, over the approximately 14-month study period.
|
|
Nodule-Level False-Negative Rate of AI and C-TIRADS
Ramy czasowe: From the preoperative examinations until the final postoperative histopathology report became available; assessed through October 15, 2025, over the approximately 14-month study period.
|
For each method, the false-negative rate is FN/(TP + FN), expressed as a percentage, among definitively malignant thyroid nodules.
AI positivity is defined as score >0.5; conventional ultrasound positivity is C-TIRADS category 4a or higher.
Include only pathology-matched nodules with an unambiguous lesion-level link and a definitive benign or malignant diagnosis.
Exclude FT-UMP, WDT-UMP, NIFTP, other borderline diagnoses, and nodules without unambiguous lesion-level linkage.
|
From the preoperative examinations until the final postoperative histopathology report became available; assessed through October 15, 2025, over the approximately 14-month study period.
|
|
Nodule-Level Positive Predictive Value of AI and C-TIRADS
Ramy czasowe: From the preoperative examinations until the final postoperative histopathology report became available; assessed through October 15, 2025, over the approximately 14-month study period.
|
For each method, positive predictive value is TP/(TP + FP), expressed as a percentage, among thyroid nodules classified as positive.
AI positivity is defined as score >0.5; conventional ultrasound positivity is C-TIRADS category 4a or higher.
Include only pathology-matched nodules with an unambiguous lesion-level link and a definitive benign or malignant diagnosis.
Exclude FT-UMP, WDT-UMP, NIFTP, other borderline diagnoses, and nodules without unambiguous lesion-level linkage.
|
From the preoperative examinations until the final postoperative histopathology report became available; assessed through October 15, 2025, over the approximately 14-month study period.
|
|
Nodule-Level Youden Index of AI and C-TIRADS
Ramy czasowe: From the preoperative examinations until the final postoperative histopathology report became available; assessed through October 15, 2025, over the approximately 14-month study period.
|
For each method, the Youden index is sensitivity + specificity - 1 using fixed binary thresholds.
AI positivity is defined as score >0.5; conventional ultrasound positivity is C-TIRADS category 4a or higher.
Include only pathology-matched nodules with an unambiguous lesion-level link and a definitive benign or malignant diagnosis.
Exclude FT-UMP, WDT-UMP, NIFTP, other borderline diagnoses, and nodules without unambiguous lesion-level linkage.
|
From the preoperative examinations until the final postoperative histopathology report became available; assessed through October 15, 2025, over the approximately 14-month study period.
|
|
Distribution of Cervical Lymph-Node Metastasis Status Among Pathologically Examined Nodes
Ramy czasowe: From surgery or supplementary sampling until the corresponding pathology result became available; assessed through October 15, 2025, over the approximately 14-month study period.
|
Among cervical lymph nodes actually removed or sampled and pathologically examined, record the number and percentage with and without metastasis.
No pathologic reference diagnosis is assigned to unsampled lymph nodes.
|
From surgery or supplementary sampling until the corresponding pathology result became available; assessed through October 15, 2025, over the approximately 14-month study period.
|
|
Nodule-Level Specificity of AI and C-TIRADS
Ramy czasowe: From the preoperative examinations until the final postoperative histopathology report became available; assessed through October 15, 2025, over the approximately 14-month study period.
|
Using definitive postoperative histopathology as the reference standard, specificity is TN/(TN + FP), expressed as a percentage, for the locked AI classification (positive if score >0.5) and conventional C-TIRADS (positive if category 4a or higher).
Include only pathology-matched nodules with an unambiguous lesion-level link and a definitive benign or malignant diagnosis.
Exclude FT-UMP, WDT-UMP, NIFTP, other borderline diagnoses, and nodules without unambiguous lesion-level linkage.
|
From the preoperative examinations until the final postoperative histopathology report became available; assessed through October 15, 2025, over the approximately 14-month study period.
|
|
Nodule-Level Negative Predictive Value of AI and C-TIRADS
Ramy czasowe: From the preoperative examinations until the final postoperative histopathology report became available; assessed through October 15, 2025, over the approximately 14-month study period.
|
Using definitive postoperative histopathology as the reference standard, negative predictive value is TN/(TN + FN), expressed as a percentage, for the locked AI classification (positive if score >0.5) and conventional C-TIRADS (positive if category 4a or higher).
Include only pathology-matched nodules with an unambiguous lesion-level link and a definitive benign or malignant diagnosis.
Exclude FT-UMP, WDT-UMP, NIFTP, other borderline diagnoses, and nodules without unambiguous lesion-level linkage.
|
From the preoperative examinations until the final postoperative histopathology report became available; assessed through October 15, 2025, over the approximately 14-month study period.
|
|
Nodule-Level Accuracy of AI and C-TIRADS
Ramy czasowe: From the preoperative examinations until the final postoperative histopathology report became available; assessed through October 15, 2025, over the approximately 14-month study period.
|
Using definitive postoperative histopathology as the reference standard, accuracy is (TP + TN)/(TP + TN + FP + FN), expressed as a percentage, for the locked AI classification (positive if score >0.5) and conventional C-TIRADS (positive if category 4a or higher).
Include only pathology-matched nodules with an unambiguous lesion-level link and a definitive benign or malignant diagnosis.
Exclude FT-UMP, WDT-UMP, NIFTP, other borderline diagnoses, and nodules without unambiguous lesion-level linkage.
|
From the preoperative examinations until the final postoperative histopathology report became available; assessed through October 15, 2025, over the approximately 14-month study period.
|
|
Area Under the ROC Curve for the Continuous AI Malignancy Score
Ramy czasowe: From the preoperative examinations until the final postoperative histopathology report became available; assessed through October 15, 2025, over the approximately 14-month study period.
|
Using definitive postoperative histopathology as the reference standard, calculate the area under the receiver operating characteristic curve for the continuous locked AI malignancy score.
Include only pathology-matched nodules with an unambiguous lesion-level link and a definitive benign or malignant diagnosis.
Exclude FT-UMP, WDT-UMP, NIFTP, other borderline diagnoses, and nodules without unambiguous lesion-level linkage.
No AUC is calculated for the single-threshold C-TIRADS classification.
|
From the preoperative examinations until the final postoperative histopathology report became available; assessed through October 15, 2025, over the approximately 14-month study period.
|
Współpracownicy i badacze
Sponsor
Sponsor
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
Rozpoczęcie studiów
Zakończenie podstawowe (Rzeczywisty)
Zakończenie podstawowe
Ukończenie studiów (Rzeczywisty)
Ukończenie studiów
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Pierwszy wysłany
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia wysłana aktualizacja
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
Inne numery identyfikacyjne badania
Inne numery identyfikacyjne badania
- AI-base PCD
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Opis planu IPD
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .